OR WAIT null SECS
The companies are working together with Japanese clients to outline projects from early clinical stage up to commercial launch.
Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced on Oct. 4, 2019 that it will further enhance and develop an existing collaboration in Japan with Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary of Sumitomo Corporation. Through its collaboration with SPI, Rentschler Biopharma has secured new contracts with Japanese pharmaceutical companies. SPI and Rentschler Biopharma are working together with Japanese clients to outline projects from early clinical stage up to commercial launch and to ensure optimal service.
Japan is the world's third largest pharmaceuticals market and is forecast to reach $89 billion to $93 billion by 2023, according to Rentschler Biopharma. There are over 100 domestic pharmaceutical companies in Japan, with many of the mid-sized and larger-sized firms in recent years developing drug candidates with innovative and new modalities, such as biologics and gene and cell therapies, for markets worldwide. Japan has also seen an increase in biopharmaceutical start-ups, which is further driving the industry's growth, the company reported.
"Our relationship with SPI has been highly productive and fruitful, and we have been impressed by their strong network and extensive experience in contract manufacturing and supply. Japanese pharmaceutical companies are playing an important and expanding role in the global healthcare market, and we are delighted to be continuing this productive collaboration as we grow our client base in Japan," said Dr. Frank Mathias, CEO of Rentschler Biopharma, in a company press release.
"We are pleased to be expanding our business with Japanese pharmaceutical companies who value Rentschler Biopharma for our excellent services, outstanding quality, and extensive track-record. We very much look forward to working together with SPI to provide clients with the best possible advice and assistance from the start of clinical trials to commercial launch," added Federico Pollano, senior vice-president, business development, Rentschler Biopharma, in the press release.
Source: Rentschler Biopharma